Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
ACCESS Newswire (Mon, 1-Jun 8:00 AM ET)
Sunshine Biopharma Approves Dilutive Share and Warrant Actions
TipRanks (Fri, 29-May 4:49 PM ET)
ACCESS Newswire (Fri, 29-May 8:00 AM ET)
Why Sunshine Biopharma (SBFM) Stock Dropped After Hours Today
Benzinga (Fri, 29-May 2:16 AM ET)
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
ACCESS Newswire (Thu, 28-May 9:00 AM ET)
Market Chameleon (Thu, 21-May 5:52 AM ET)
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
ACCESS Newswire (Thu, 21-May 7:00 AM ET)
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
ACCESS Newswire (Tue, 19-May 12:08 PM ET)
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
ACCESS Newswire (Mon, 18-May 12:17 PM ET)
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
ACCESS Newswire (Mon, 6-Apr 8:30 AM ET)
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
Sunshine Biopharma trades on the NASDAQ stock market under the symbol SBFM.
As of June 2, 2026, SBFM stock price climbed to $2.60 with 2,868,535 million shares trading.
SBFM has a beta of 1.52, meaning it tends to be more sensitive to market movements. SBFM has a correlation of 0.01 to the broad based SPY ETF.
SBFM has a market cap of $4.20 million. This is considered a Sub-Micro Cap stock.
Last quarter Sunshine Biopharma reported $8 million in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.09.
In the last 3 years, SBFM traded as high as $13,402.00 and as low as $2.11.
SBFM has underperformed the market in the last year with a price return of -81.7% while the SPY ETF gained +29.4%. SBFM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -77.6% and -40.9%, respectively, while the SPY returned +10.9% and +3.5%, respectively.
SBFM support price is $2.10 and resistance is $2.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SBFM shares will trade within this expected range on the day.